NuCana (NCNA) Cash & Equivalents (2015 - 2025)
NuCana (NCNA) reported Cash & Equivalents of $32.3 million for Q4 2025, up 272.39% on a YoY basis from $8.7 million in Q4 2024, and down 5.32% sequentially from $34.1 million in Q3 2025.
NuCana (NCNA) Cash & Equivalents (2015 - 2025) Analysis & Trends
NuCana (NCNA) has 11 years of Cash & Equivalents data on file, last reported at $32.3 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents rose 272.39% year-over-year to $32.3 million; the trailing twelve-month figure through Dec 2025 stood at $32.3 million (up 272.39% YoY), and the FY2025 full-year result was $32.0 million, up 270.64% from the prior year.
- Cash & Equivalents retreated to $32.3 million in Q4 2025, from $34.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $108.4 million in Q1 2021 to a low of $5.0 million in Q1 2025.
- A 5-year average of $43.9 million and a median of $33.2 million in 2025 frame the typical range for Cash & Equivalents.
- Peak annual rise in Cash & Equivalents reached 272.39% in 2025, while the deepest fall reached 69.5% in 2025.
- Tracing NCNA's Cash & Equivalents over 5 years: stood at $81.2 million in 2021, then tumbled by 39.49% to $49.2 million in 2022, then plunged by 56.51% to $21.4 million in 2023, then plunged by 59.48% to $8.7 million in 2024, then surged by 272.39% to $32.3 million in 2025.
- Business Quant data shows NCNA's Cash & Equivalents at $32.3 million in Q4 2025, $34.1 million in Q3 2025, and $11.3 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 1.71 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.26 Mn |
| Sep 30, 2025 | 34.07 Mn |
| Jun 30, 2025 | 11.26 Mn |
| Mar 31, 2025 | 4.98 Mn |
| Dec 31, 2024 | 8.66 Mn |
| Sep 30, 2024 | 14.75 Mn |
| Jun 30, 2024 | 14.69 Mn |
| Mar 31, 2024 | 16.32 Mn |
| Dec 31, 2023 | 21.38 Mn |
| Sep 30, 2023 | 22.55 Mn |
| Jun 30, 2023 | 30.84 Mn |
| Mar 31, 2023 | 37.68 Mn |
| Dec 31, 2022 | 49.16 Mn |
| Sep 30, 2022 | 59.81 Mn |
| Jun 30, 2022 | 58.59 Mn |
| Mar 31, 2022 | 70.53 Mn |
| Dec 31, 2021 | 81.24 Mn |
| Sep 30, 2021 | 97.92 Mn |
| Jun 30, 2021 | 102.62 Mn |
| Mar 31, 2021 | 108.42 Mn |